From the lab to the headlines.

TFG-001, A NOVEL 3D NEURAL MICROTISSUE CELL THERAPY, DEMONSTRATES SUPERIOR FUNCTIONALITY AND REINNERVATION FOR PARKINSON’S DISEASE

BORDEAUX, France – May 25, 2026 – TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new...

In the Stem Cell Jungle #3

Welcome to the third edition of our factsheets. Here we dive in to discuss the distinct approaches and mechanisms of action of gene versus cell...

In the Stem Cell Jungle #2

In factsheet one, we introduced cell therapy and the immense potential it has to help millions of patients suffering from diseases such as neurodegenerative diseases...

In the Stem Cell Jungle #1 Factsheet

Regenerative medicine holds huge promise for the future and the recent approvals of the first iPSC-derived cell therapies (in Parkinson’s disease and heart failure) are...

TREEFROG THERAPEUTICS ANNOUNCES CHANGES TO EXECUTIVE COMMITTEE WITH THE ARRIVAL OF MARK ROTHERA AS CHIEF EXECUTIVE OFFICER & BOARD MEMBER TO SPEARHEAD NEXT PHASE OF GROWTH

BORDEAUX, December 16th, 2025 — TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted...

TREEFROG THERAPEUTICS SECURES €30 MILLION FROM EUROPEAN INVESTMENT BANK (EIB) MARKING A SIGNIFICANT MILESTONE IN THE COMPANY’S JOURNEY TO ACCELERATE THE FIELD OF CELL THERAPY

BORDEAUX, May 27, 2025 TreeFrog Therapeutics, a French biotech specializing in cell therapy has secured a €30 million financing from the European Investment Bank (EIB)....

TREEFROG THERAPEUTICS PRESENTS DELIVERY STRATEGY FOR NEXT GENERATION 3D CELL THERAPY FORMAT FOR PARKINSON’S DISEASE AT THE 28TH ANNUAL ASGCT MEETING IN NEW ORLEANS  

BORDEAUX, May 13th, 2025 — TreeFrog Therapeutics, a French biotech specializing in cell therapy is the first company to present a clinical-ready delivery strategy for...

Overview of Parkinson’s Disease Clinical Trial Landscape

Welcome to the second article in our series that presents the findings of our analysis on the market evolution of regenerative medicine in cell therapy....

White Paper: The hiPSC lumenized rosette

This white paper examines how human pluripotent stem cells (hPSCs) exist in their natural developmental environment, within three-dimensional lumenized rosette structures rather than traditional 2D...

TreeFrog Therapeutics’ poster – Scaling-up iPSC based cell therapies

TreeFrog Therapeutics’ scientific poster on scaling-up iPSC-based cell therapies with the C-Stem™ platform (JSRM 2024).

TreeFrog Therapeutics’ poster – Parkinson’s disease

TreeFrog Therapeutics’ scientific poster on its cell therapy approach to Parkinson’s disease, presenting the 3D neural microtissue (TFG-001) programme.

TREEFROG THERAPEUTICS ENTERS INTO PIONEERING RESEARCH COLLABORATION IN IMMUNO-ONCOLOGY WITH THE UNIVERSITY OF PITTSBURGH

TREEFROG THERAPEUTICS ENTERS INTO PIONEERING RESEARCH COLLABORATION IN IMMUNO-ONCOLOGY WITH THE UNIVERSITY OF PITTSBURGH

Overview of iPSC Clinical Trials Landscape

Regenerative medicine holds immense potential to bring new treatments to patients with high unmet medical needs or, indeed, solutions for diseases with no existing treatment...

TREEFROG PUBLISHES RESULTS OF FIRST SUCCESSFUL BIOPRODUCTION OF A PARKINSON’S DISEASE CELL THERAPY IN SCALABLE BIOREACTOR IN NEUROTHERAPEUTICS JOURNAL

Publication demonstrates the cell therapy product for Parkinson’s Disease overcomes most complex challenges in bioproduction, while demonstrating full behavioral recovery in pre-clinical model BORDEAUX, France,...

TREEFROG THERAPEUTICS PARTICIPATES IN AN INNOVATION SHOWCASE & POSTER SESSION AT THE INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH (ISSCR) ANNUAL MEETING

TreeFrog Therapeutics Picks-Up Best Poster Award At The International Society For Cell & Gene Therapy (ISCT) Annual Meeting For Their Cell Therapy Program In Parkinson’s Disease

TreeFrog Therapeutics Picks-Up Best Poster Award At The International Society For Cell & Gene Therapy (ISCT) Annual Meeting For Their Cell Therapy Program In Parkinson’s...

TreeFrog Presents Data From Their Parkinson’s Disease Cell Therapy Program At The 29th World Congress On Parkinson’s Disease And Related Disorders (IAPRD) In Lisbon

TreeFrog Presents Data From Their Parkinson’s Disease Cell Therapy Program At The 29th World Congress On Parkinson’s Disease And Related Disorders (IAPRD) In Lisbon

Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes

Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes

TreeFrog Presents Data From Their Parkinson’s Cell Therapy Program At The American Academy Of Neurology Annual Meeting

TreeFrog Presents Data From Their Parkinson’s Cell Therapy Program At The American Academy Of Neurology Annual Meeting

TreeFrog’s Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

TreeFrog’s Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

TreeFrog Therapeutics reinforces Executive Committee with three new members

TreeFrog Therapeutics reinforces Executive Committee with three new members.

Exponential hiPSC expansion in 10L bioreactors with C-Stem™ published in Biomaterials

This new paper dedicated to hiPSC expansion with the C-Stem™ technology platform shows that: hiPSCs seeded in C-Stem™-generated capsules self-organize into in vivo-like 3D lumenized...

Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors

GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of...

Our blog “In the Stem Cell Jungle” is out

In the 2023, the webcast “In the Stem Cell Jungle” hosted by Maxime Feyeux, co-founder and CSO of TreeFrog Therapeutics becomes a blog. What will...

Engineering 3D micro-compartments for highly efficient and scale-independent expansion of human pluripotent stem cells in bioreactors

Cohen PJR, Luquet E, Pletenka J, Leonard A, Warter E, Gurchenkov B, Carrere J, Rieu C, Hardouin J, Moncaubeig F, Lanero M, Quelennec E, Wurtz...

TreeFrog Therapeutics moves to GMP manufacturing with cell encapsulation device delivered by Invetech

The machine will be transferred in 2023 to a contract development and manufacturing organization (CDMO) to produce TreeFrog’s cell therapy candidate for Parkinson’s disease, with...

Peter Nell joins TreeFrog Therapeutics as Independent Board Member

Bordeaux, France / July 7th, 2022 – Peter Nell, Ph.D., was appointed independent board member of TreeFrog Therapeutics. Peter Nell led business development and corporate...

Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology

Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic platform for the mass-production of iPSC-derived cell...

TreeFrog Therapeutics expands Board with new independent members from the cell therapy industry

TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today...

TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies

TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today...

EIC ScalingUp TOP50: TreeFrog Therapeutics selected among 3,000 European Deeptech companies

Throughout 2022, TreeFrog Therapeutics will be connected to strategic international investors through the EIC ScaleUp initiative. Selected among 3,000+ deeptech companies funded by the €10.1...

TreeFrog Therapeutics back in the FrenchTech120

The whole team at TreeFrog Therapeutics wishes you a Happy New Year !

TreeFrog celebrates its third birthday, announcing a two-fold increase in lab capacity !

TreeFrog Therapeutics celebrated its 3rd anniversary on December 7th, 2021, announcing that the company increase its clean room capacity by two-fold in Pessac, to support...

TreeFrog Therapeutics Awarded the Galien MedStartup Prize 2020 for its International Consortium on iPSC Quality with US, Japan & France

October 28th 2021, Anthony Renodon, U.S. representative of TreeFrog Therapeutics received The Prix Galien MedStartUp 2020 in New York.   Awarded on October 26th 2020...

TreeFrog Therapeutics secures $75M in Series B financing to advance a pipeline of stem cell-derived cell therapies and deploy proprietary C-Stem™ technology in the USA & Japan

TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the...

Leap forward in cell therapy manufacturing: data reveals highly reproducible stem cell expansion in 10L bioreactors, with exponential growth and preserved quality

TreeFrog Therapeutics announces the results of two runs of hiPSC amplification in 10L bioreactors at the Annual Meeting of the International Society for Stem Cell...

C-Stem™ outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells

La technologie biomimétique de TreeFrog Therapeutics repousse les limites de la production industrielle de thérapies cellulaires issues de cellules souches. La société vient de produire...

World first: TreeFrog Therapeutics announces the production of a single batch of 15 billion iPS cells in a 10L bioreactor with exponential amplification of 276-fold per week.

Biomimetic 3D cell culture technology unlocks the manufacturing bottleneck of stem-cell derived cell therapies through exponential hiPSC growth in large-scale bioreactors, with best-in-class cell quality. ...

TreeFrog Therapeutics（仏国ボルドー）、iPS細胞の品質に関する国際コンソーシアムでGalien MedStartup Prizeを受賞

https://youtu.be/E7MvA1O_gUA ガリアン賞のメディカルスタートアップアワード（Prix Galien MedStartup）の授賞式が2020年10月26日、米国ボストンで開催され、細胞治療を専門とするフランスのバイオテクノロジー企業TreeFrog Therapeuticsが主導するQC-Stemコンソーシアムが、受賞の栄誉に輝きました。QC-Stemには、アメリカ、フランス、日本の各国から、iPS細胞の品質に関する世界最高レベルの科学者たちが参加しています。今後数ヶ月間にわたり、iPS細胞の大量生産のためにTreeFrog Therapeuticsが開発した新技術をQC-Stemの専門家たちが評価します。   安全で安価なiPS細胞由来の細胞治療の大量生産を可能にする破壊的技術の開発を手掛けるフランスのバイオテクノロジー企業TreeFrog Therapeuticsは、2020年10月26日にボストンで開催されバーチャル授賞式で、名誉あるガリアン賞のメディカルスタートアップアワードを受賞しました。「バイオ医薬品業界」部門における、QC-Stemプロジェクトに対しての受賞です。QC-Stemは、神戸医療産業都市推進機構（日本神戸）、ハーバード幹細胞研究所およびダナ・ファーバー癌研究所（米国ボストン）、イマジン研究所（仏国パリ）の専門家たちが参加する国際コンソーシアムで、TreeFrog Therapeutics独自のC-StemTMテクノロジーにより生産される多能性幹細胞の品質評価を目的としています。   iPS細胞の品質：細胞治療業界の重要課題   全世界の細胞治療業界に対する2020年上半期の投資額は75億ドルと、2019年上半期と比較して387％増加しました[1]。同業界では、高品質で低コストな大量の治療用細胞の生産が必要とされており、この点で、iPS細胞は非常に魅力的な技術です。体内のほぼすべての細胞から得られるiPS細胞は、どのような治療用細胞においても増殖、分化できます。 しかしながら、現在の細胞培養プロセスは規模が限定されており、そうした壊れやすい細胞にダメージを与えるもので、それにより細胞死が引き起こされるか、遺伝的完全性が損なわれてしまいます。2012年にノーベル賞を受賞した山中伸弥教授が最近の論文[2]で指摘している通り、従来型のヒトiPS細胞の二次元培養は、本質的に腫瘍形成のリスクを伴うものです。「［多能性幹］細胞のin vitro増殖培養は、染色体異常、遺伝子コピー数変異（CNV）や一塩基変異といった遺伝子変化を必然的に引き起こす」のです。     C-StemTM：規模と品質の飛躍的進化を実現   TreeFrog Therapeuticsは、細胞治療の製造における致命的なボトルネックへの取り組みを通じて、独自技術のC-StemTMをさらに進化させています。C-StemTMはハイスループットの細胞カプセル化（1秒あたり1,000個のカプセルを生産）をベースとした技術で、それにより培養プロセス全体を通じた細胞の保護が可能となり、産業用バイオリアクターによるiPS細胞の大規模な増幅および分化を低コストで実現できます。   「C-StemTMですでに生産コストを10分の1に削減することが可能ですが、弊社が今後数年で目指しているのは、コストを100分の1に削減し、さらに大勢の患者の方々が細胞治療を受けられるようにすることです。QC-Stemコンソーシアムにより、弊社の生体模倣の三次元培養システムが適正な細胞分裂も促進させることを実証し、それによりiPS細胞由来の治療用細胞の品質と安全性に新たな基準をもたらすことを目標にしています。細胞治療品質に関する世界最高レベルの専門家たちと一緒に仕事ができ、とても興奮しています。たとえば、川真田伸教授との共同作業により、日本が過去16年にわたり培ってきた、iPS細胞治療の先駆的ノウハウの恩恵を受けることができるのです。」 マクシム・フェイユー（TreeFrog...

The French Blood Agency announces agreement with TreeFrog Therapeutics to scale-up manufacturing of iPS-derived hematopoietic stem cell transplants

TreeFrog Therapeutics will apply its proprietary technology for the mass-production of stem cell therapies to the world-first single-step protocol allowing the differentiation of human induced...

Presenting our cell therapy program for Parkinson’s disease at Nectar 2020 !

https://youtu.be/2ucSbVeq3V4 Good news ! Emilie Faggiani, who leads the cell therapy programme for Parkinson’s disease at TreeFrog, was selected to talk at the 30th Annual Meeting...

TreeFrog Therapeutics and Invetech expand partnership to transition high-throughput stem cell encapsulation technology to GMP system for commercial-scale cell therapy manufacturing

https://youtu.be/SW25zIr_QR8 The two companies started their collaboration in 2019 to industrialize TreeFrog’s stem cell encapsulation technology, to enable the mass production of hPSC-derived cell therapies...

TreeFrog nominated for the Prix Galien MedStartup Award !

We are glad to announce that we are nominated for Prix Galien MedStartup in the category “Pharmaceutical and Biotechnology” ! This prize, by the prestigious Galien...

TreeFrog joins the Japanese Society for Regenerative Medicine

TreeFrog Therapeutics today joins the Japanese Society for Regenerative Medicine (JSRM). Already present in Japan with a local Business Development Officer – Etsuko Takanashi – the French company...

360° video of our first industrial site !

https://youtu.be/Fid46y9rJOI 5 street artists from Bordeaux were  given carte blanche to paint our first industrial site (1,200sqm or 13,000 sq ft)

Press Release : TreeFrog Therapeutics opens its first facility dedicated to iPS cell therapy scale-up in Bordeaux, France

Reaching a new milestone in the industrial implementation of the C-StemTM technology, TreeFrog Therapeutics announces the opening of a 13,000 sq ft facility aimed at scaling-up cell...

C-Stem™ technology presented in London

Today, Andrea Leonoard, Senior Scientist at TreeFrog Therapeutics was in London, UK to speak at the 3D Cell Culture Conference. She gave an invited presentation about the C-Stem™,...

Press Release : TreeFrog Therapeutics brings in senior profiles to drive the advent of high-quality & affordable allogenic cell therapies

Senior profiles from Merck KGaA and FUJIFILM Cellular Dynamics join in to accelerate the global dissemination of proprietary C-StemTM technology for cell therapy mass-production. Bordeaux, France, February 5,...

TreeFrog Therapeutics now part of the French Tech 120 !

https://youtu.be/9mHe_hMDCuY TreeFrog Therapeutics was selected to join the French Tech 120 !  Launched by the French government, this program dedicated to startups in the hyper-growth...

New video : How do we reduce cell therapy costs ?

https://youtu.be/OcfDgqEftE4 TreeFrog Therapeutics starts 2020 with a new video, recapitulating the benefits of C-Stem™ to provide access for millions of patients to safe and affordable...

Role of mechanical cues and hypoxia on the growth of tumor cells in strong and weak confinement

Le Maout V, Alessandri K, Gurchenkov B, Bertin H, Nassoy P, Sciumè G Sci Adv, 2020; 6(13):eaaz7130. doi:10.1126/sciadv.aaz7130 · PMID 32232163

Buckling of an Epithelium Growing under Spherical Confinement

Trushko A, Di Meglio I, Merzouki A, Blanch-Mercader C, Abuhattum S, Guck J, Alessandri K, Nassoy P, Kruse K, Chopard B, Roux A Dev Cell,...

TreeFrog named Deep Tech Pioneer

TreeFrog Therapeutics has been named one of Hello Tomorrow’s Deep Tech Pioneers! Selected among more than 5,000 startups from 128 different countries that applied to the...

TreeFrog in Boston !

TreeFrog Therapeutics’ CEO/CTO, Kevin Alessandri is spending a week in Boston (Novembre 4-9) as part of the New Technology Venture Accelerator (NETVA) program to meet the local...

TreeFrog Therapeutics at BIG by BPIfrance

https://youtu.be/Fqn098sYBzc Our CSO, Maxime Feyeux, contributed to a roundtable entitled “What breakthrough innovations to develop next-generation bioproduction factories ?” organized by BPI France and Medicen...

Press release : TreeFrog Therapeutics receives additional €3M non-dilutive funding

TreeFrog Therapeutics receives additional €3M non-dilutive funding to mass-produce clinical-grade cell therapies by 2021   Company awarded close to €3M ($3.3M) in public grants only...

New video ! How do we mass-produce stem cells ?

https://youtu.be/e4CbJv0T_ug TreeFrog Therapeutics has developed C-Stem™ : a proprietary technology platform for the mass-production of iPSc-based cell therapies. C-Stem™ secures cell quality (100% genomic integrity),...

TreeFrog Therapeutics raises over €7M ($7.8M)

TreeFrog Therapeutics raises over €7M ($7.8M) in Series A financing round 6 months after incorporation Funding to scale-up company’s proprietary technology C-Stem™ for mass-production of...

Press release : TreeFrog Therapeutics delivers first batch of Stem Cells (hIPS), with best in class quality check, to cell and gene therapy leader Imagine Institute

C- Stem™ technology introduces a new standard for hIPS suspension culture. Based on biomimetic stem cell culture in 3D, C- Stem™ enables cell therapy production scale-up...

New video : How do we encapsulate stem cells ?

This new explainer video provides a quick overview of C-Stem™, the patented technology operated by TreeFrog Therapeutics to mass-produce stem cells for cell therapy.

Press release : TreeFrog Therapeutics announces licence agreement with Aquitaine Science Transfert

https://youtu.be/b7y8YHiqlNI “Four months after its creation, TreeFrog Therapeutic announces license agreement with tech transfer office Aquitaine Science Transfert to industrialize and commercialize a breakthrough technology based on...

Detection of all adult Tau isoforms in a 3D culture model of iPSC-derived neurons

Miguel L, Rovelet-Lecrux A, Feyeux M, Frebourg T, Nassoy P, Campion D, Lecourtois M Stem Cell Res, 2019; 40:101541. doi:10.1016/j.scr.2019.101541 · PMID 31522011

A model of guided cell self-organization for rapid and spontaneous formation of functional vessels

Andrique L, Recher G, Alessandri K, Pujol N, Feyeux M, Bon P, Cognet L, Nassoy P, Bikfalvi A Sci Adv, 2019; 5(6):eaau6562. doi:10.1126/sciadv.aau6562 · PMID...

Quantitative cell-based model predicts mechanical stress response of growing tumor spheroids over various growth conditions and cell lines

Van Liedekerke P, Neitsch J, Johann T, Alessandri K, Nassoy P, Drasdo D PLoS Comput Biol, 2019; 15(3):e1006273. doi:10.1371/journal.pcbi.1006273 · PMID 30849070

Vidéo : Treefrog founders at the i-LAB ceremony

treefrog therapeutics i-lab bpifrance

TreeFrog wins the i-LAB innovation contest

We are very proud to announce that we have been awarded the 2018 I-Lab Great Prize. The I-Lab competition is organized by BPIfrance and the...

Organ size control via hydraulically gated oscillations

Ruiz-Herrero T, Alessandri K, Gurchenkov BV, Nassoy P, Mahadevan L Development, 2017; 144(23):4422-4427. doi:10.1242/dev.153056 · PMID 29183945

A 3D printed microfluidic device for production of functionalized hydrogel microcapsules for culture and differentiation of human Neuronal Stem Cells

Alessandri K, Feyeux M, Gurchenkov B, Delgado C, Trushko A, Krause KH, Vignjević D, Nassoy P, Roux A Lab Chip, 2016; 16(9):1593-604. doi:10.1039/c6lc00133e · PMID...

Controlled production of sub-millimeter liquid core hydrogel capsules for parallelized 3D cell culture

Doméjean H, de la Motte Saint Pierre M, Funfak A, Atrux-Tallau N, Alessandri K, Nassoy P, Bibette J, Bremond N Lab Chip, 2016; 17(1):110-119. doi:10.1039/c6lc00848h...

Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells

Drouet V, Ruiz M, Zala D, Feyeux M, Auregan G, Cambon K, Troquier L, Carpentier J, Aubert S, Merienne N, Bourgois-Rocha F, Hassig R, Rey...

Screening of bioactive peptides using an embryonic stem cell-based neurodifferentiation assay

Xu R, Feyeux M, Julien S, Nemes C, Albrechtsen M, Dinnyés A, Krause KH AAPS J, 2014; 16(3):400-12. doi:10.1208/s12248-014-9578-7 · PMID 24557747

Cellular capsules as a tool for multicellular spheroid production and for investigating the mechanics of tumor progression in vitro

Alessandri K, Sarangi BR, Gurchenkov VV, Sinha B, Kießling TR, Fetler L, Rico F, Scheuring S, Lamaze C, Simon A, Geraldo S, Vignjevic D, Doméjean...

High throughput screening for inhibitors of REST in neural derivatives of human embryonic stem cells reveals a chemical compound that promotes expression of neuronal genes

Charbord J, Poydenot P, Bonnefond C, Feyeux M, Casagrande F, Brinon B, Francelle L, Aurégan G, Guillermier M, Cailleret M, Viegas P, Nicoleau C, Martinat...

Early transcriptional changes linked to naturally occurring Huntington’s disease mutations in neural derivatives of human embryonic stem cells

Feyeux M, Bourgois-Rocha F, Redfern A, Giles P, Lefort N, Aubert S, Bonnefond C, Bugi A, Ruiz M, Deglon N, Jones L, Peschanski M, Allen...

Human embryonic stem cells reveal recurrent genomic instability at 20q11.21

Lefort N, Feyeux M, Bas C, Féraud O, Bennaceur-Griscelli A, Tachdjian G, Peschanski M, Perrier AL Nat Biotechnol, 2008; 26(12):1364-6. doi:10.1038/nbt.1509 · PMID 19029913